

ABSTRACT

Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as
5 an active ingredient.

The preparations provides such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.

2025 RELEASE UNDER E.O. 14176